지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2009.12
- 수록면
- 174 - 182 (9page)
이용수
초록· 키워드
오류제보하기
Objectives: The purpose of this study is to assess the subjective quality of life in stable but symptomatic patients with schizophrenia switched from risperidone or olanzapine to ziprasidone. And we investigated how the subjective quality of life is related with depression, drug attitude, drug satisfaction and psychopathology of schizophrenia.
Methods: Twenty-three schizophrenic patients in 3 hospitals were switched to an 8-week, open label, flexible dose(80-160㎎/day) of ziprasidone. Psychiatric status was evaluated by Korean version of 4th Revision of Schizophrenia Quality of Life Scale(SQLS-R4K), Korean version of Calgary Depression Scale for Schizophrenia(KCDSS), Korean version of Drug Attitude Inventory(KDAI-10), Drug Satisfaction Questionaire(DSQ), Positive and Negative Syndrome Scale(PANSS), and Clinical Global Impression scale(CGI) at baseline, day 1, week 4 and week 8.
Results: Subjective quality of life and depressive symptom were not improved significantly after switching to ziprasidone. Subjective quality of life was related significantly with depressive symptoms and drug attitude, but not drug satisfaction. Subjective quality of life correlated significantly with total scores and positive symptom scores in PANSS and CGI-S.
Conclusion: This study suggests that the subjective quality of life of schizophrenia, who had treated by prior atypical antipsychotics, is not influenced significantly by switching to ziprasidone. Active management for depressive and positive symptoms, and drug side effect is recommended to improve patients' quality of life.
Methods: Twenty-three schizophrenic patients in 3 hospitals were switched to an 8-week, open label, flexible dose(80-160㎎/day) of ziprasidone. Psychiatric status was evaluated by Korean version of 4th Revision of Schizophrenia Quality of Life Scale(SQLS-R4K), Korean version of Calgary Depression Scale for Schizophrenia(KCDSS), Korean version of Drug Attitude Inventory(KDAI-10), Drug Satisfaction Questionaire(DSQ), Positive and Negative Syndrome Scale(PANSS), and Clinical Global Impression scale(CGI) at baseline, day 1, week 4 and week 8.
Results: Subjective quality of life and depressive symptom were not improved significantly after switching to ziprasidone. Subjective quality of life was related significantly with depressive symptoms and drug attitude, but not drug satisfaction. Subjective quality of life correlated significantly with total scores and positive symptom scores in PANSS and CGI-S.
Conclusion: This study suggests that the subjective quality of life of schizophrenia, who had treated by prior atypical antipsychotics, is not influenced significantly by switching to ziprasidone. Active management for depressive and positive symptoms, and drug side effect is recommended to improve patients' quality of life.
목차
서론
방법
결과
고찰
감사의 글
참고문헌
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Amisulpride를 투여한 급성기 정신분열병 환자에서 주관적 삶의 질
생물치료정신의학
2010 .06
-
Ziprasidone의 자연적 임상경험에 대한 후향적 조사 연구 : 3개 대학병원의 경험
신경정신의학
2007 .01
-
리스페리돈(Risperidone)을 투약 중인 정신분열병 환자에서 지프라시돈(Ziprasidone)으로 교체 투약 시 보이는 임상적 및 대사적 이득에 대한 전향적 개방 연구
생물치료정신의학
2009 .06
-
The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
PSYCHIATRY INVESTIGATION
2014 .01
-
섬망 치료에 있어서 지프라시돈(Ziprasidone)과 리스페리돈(Risperidone)의 효과 비교
생물치료정신의학
2009 .06
-
An Inter-Ethnic Comparison Study of Ziprasidone Plasma Levels, Dosage and Clinical Response in Patients with Schizophrenia
PSYCHIATRY INVESTIGATION
2017 .01
-
Ziprasidone for the Treatment of Delirium: Case Studies
Clinical Psychopharmacology and Neuroscience
2010 .01
-
정신분열병 환자의 우울증상 및 정서인식이 삶의 질에 미치는 영향
생물치료정신의학
2012 .06
-
Effect of Initial Ziprasidone Dose on Treatment Outcome of Korean Patients with Acute Manic or Mixed Episodes
PSYCHIATRY INVESTIGATION
2011 .01
-
체중증가 발생 가능성에 따른 항정신병약물 네 군 간의 정신분열병 환자의 주관적 삶의 질 비교 연구
신경정신의학
2011 .01
-
입원중인 만성 정신분열병환자의 삶의 질과 정신병리의 관계
생물치료정신의학
2007 .06
-
Understanding The Cause of and Developing New Drugs for Schizophrenia
대한약학회 학술대회
2000 .01
-
Subjective Well-being in Patients with Schizophrenia Treated with Atypical Antipsychotics: The Impact of Psychopathology and Adverse Drug Effects
Clinical Psychopharmacology and Neuroscience
2010 .01
-
조현병 환자의 삶의 질에 영향을 끼치는 정신내적 요인 탐색
대한조현병학회지
2018 .01
-
정신분열병 또는 정신분열형장애를 가진 입원환자에서 Risperidone과 Olanzapine의 효과의 비교 : 6주간의 개방적 전향적 연구
생물치료정신의학
2003 .12
-
정신분열병 환자의 삶의 질과 정신사회적 특성과의 관계
신경정신의학
2004 .01
-
한국어판 정신분열병 삶의 질 척도의 개발과 PANSS와의 관련성
신경정신의학
2006 .01
-
정신분열병 입원환자의 우울증상 유병 률 및 예측인자
생물치료정신의학
2011 .06
-
일 대학병원 유방암 환자의 우울증상과 삶의 질
정신신체의학
2013 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2010-513-001908182